Oculus Innovative Sciences, Inc. Development Partner, Bayer Animal Health, Receives Regulatory Approvals to Market Microcyn(R)-Based Vetericyn(TM) Animal Healthcare Products in China and Taiwan

Published: Nov 13, 2009

Bookmark and Share

PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat chronic and acute wounds, today announced that its development partners, Bayer Animal Health divisions in China and Taiwan, recently secured regulatory approvals in both those countries to develop and market Microcyn-based Vetericyn™ products for their respective animal healthcare markets.

Back to news